 |
|
|
| |
MK-8591 Does Not Alter the Pharmacokinetics of the Oral
Contraceptives Levonorgestrel and Ethinyl Estradiol
|
| |
| |
MK-8591 is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) with potent antiviral activity against wild-type and drug-resistant HIV-1 variants that is currently under development for treatment of HIV infection
Reported by Jules Levin
&
IDWeek 2018; San Francisco, CA, USA; October 3-7, 2018.
W. Ankrom1; D. Jonathan1; D. Jackson Rudd1; S. Zhang1; K. Fillgrove1; K. Gravesande1;
R. Matthews1; D. Brimhall2; S.A. Stoch1; M. Iwamoto1
1Merck & Co., Inc., Kenilworth, NJ, USA; 2Novum, Las Vegas, NV, USA
|
| |
|
|
|
|
|
